Contact

Our portfolio

AMI Pharma

AMI Pharma develops therapeutics compounds for Type 1 Diabetes and autoimmune diseases. Their research, based on IP from Amsterdam UMC and Wageningen University & Research, aims to bring new treatments to the clinical trials. AMI Pharma leverages extensive pre-clinical and clinical data to advance their therapeutic pipeline.

  • Institute: Amsterdam UMC
Industry: Diabetes, Metabolic Disorders, Therapeutics
  • Founding year: 2022
Visit website

Want to get in contact about AMI Pharma?

We’re happy to connect. Reach out to our investment manager working with the team to learn more or explore potential opportunities.

Browse all investment managers

Marc Roelofs

Life Science & Health

Our portfolio

Check out similar ventures

AtMoves
Improving orthopedic diagnostics with advanced joint loading device and AI-based imaging technology.
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
AlpENa Biosciences
Developing bispecific antibodies as enhanced cancer immunotherapy.
Skyline Dx
Advancing molecular diagnostics for precision oncology and infectious diseases.
AtMoves
Improving orthopedic diagnostics with advanced joint loading device and AI-based imaging technology.
Phlox Therapeutics
Developing RNA-based therapies for rare genetic heart diseases.
AlpENa Biosciences
Developing bispecific antibodies as enhanced cancer immunotherapy.
Skyline Dx
Advancing molecular diagnostics for precision oncology and infectious diseases.
Explore full AAV portfolio
Contact